CA-VISA
21.12.2021 12:02:09 CET | Business Wire | Press release
Visa (NYSE:V) today announced it has further expanded its support of women’s football by becoming the first Women’s Football Partner for the FIFA Women’s World Cup 2023™. This investment builds on long-term commitments Visa has made across Europe and around the world, to help elevate women’s football and usher in greater equality within the sport.
“Women are a force to be reckoned with – on the pitch, as small business owners, and as drivers of a majority of consumer purchases. We know that when we support the success of women in sport, we support the success of women everywhere,” said Lynne Biggar, Chief Marketing Officer, Visa. “Becoming the first FIFA Women’s Football Partner is part of a much larger investment in women’s initiatives to help recognize the limitless potential of women around the world.”
Visa is one of the world’s most active sponsors of women’s football. Through the company’s sponsorship of the FIFA Women's World Cup 2023™ and other leading women’s football organizations around the world, the company strives to be a catalyst for change and contribute to the growing recognition of women’s football. The FIFA Women's World Cup 2019™ tournament was watched by a record 1.12 billion viewers1 and marked Visa’s largest onsite investment in women’s football, providing the latest payment technology at all venues and curating exclusive experiences for consumers and clients from around the world.
As the FIFA Women’s World Cup™ heads to Australia and New Zealand in 2023, marking the first time the Tournament will be played across two countries and be expanded to 32 teams, Visa will enable similar one-of-a-kind experiences for football fans globally, activate the Player of the Match award and incorporate its Team Visa program for women footballers. Additionally, as the Exclusive Payment Service for the FIFA Women’s World Cup 2023™, Visa will implement its innovative payment technology at tournament venues and deliver exclusive experiences for fans and clients, ranging from delivering innovative ways to pay to utilizing Visa’s exclusive marketing campaign assets to drive mutual business priorities with clients.
“As a long-standing FIFA Partner and a proud supporter of women’s football, it was a natural choice for Visa to become the first ever Women’s Football Partner at FIFA,” said Sarai Bareman, FIFA’s Chief Women’s Football Officer. “Visa is well known for supporting athletes and seeing the positive benefits that can come through sport. They are advocates for equality, diversity, and inclusion, core values that are shared by FIFA and the FIFA Women’s World Cup, as we grow and celebrate the women’s game.”
Given the correlation between success in sport and business – 94% of women in the C-suite have played a sport at some time in their lives2 – Visa’s support for women does not end on the pitch. Visa continues to develop programs that open more opportunities for women on and off the field:
- Team Visa: Designed to help athletes succeed in their athletic career and beyond, Team Visa has championed more than 500 athletes since its inception. Of those athletes, 55% are women, including 22 female footballers such as Lucy Bronze (England), Alexia Putellas (Spain) and Ellie Carpenter (Australia).
- The Second Half: Launched in the UK in early 2021, the Second Half is a Visa career development program to support female footballers as they consider careers beyond football. The program helps women recognize how to translate the skills they have developed – perseverance, teamwork, and commitment – outside of sport.
- She’s Next, Empowered by Visa: Broader Visa programs – such as She’s Next – support women entrepreneurs around the world and work to close gaps with educational tools, mentorship and meaningful funding.
“I love having the opportunity to encourage young people to chase their dreams and am so proud to be part of Team Visa because the company shares this same vision and supports what I do,” said Ellie Carpenter, defender on Australia’s national women’s football team. “To be looking ahead toward playing the FIFA Women’s World Cup 2023™ in my home country is an absolute dream come true.”
Visa’s first-ever sponsorship of the FIFA Women’s World Cup 2023™ complements its global investment in women’s football , including its ground-breaking partnership with UEFA Women’s Football, and sponsorship of the U.S. Soccer Federation, including the U.S. Women’s National Team and the SheBelieves Cup. It also builds on Visa’s longstanding partnership with FIFA, including the FIFA World Cup™, FIFA Women's World Cup™ and other FIFA events.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating more than 215 billion payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories each year. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com
.
____________________
1
FIFA
, October 2019
2
EY, “Why a Female Athlete Should Be Your Next Leader”
, September 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom